헬스케어 수탁제조 시장 시장 규모, 점유율, 동향 분석 보고서 : 유형별(의료기기, 의약품), 최종 용도별(의료기기 기업), 지역별, 부문별 예측(2023-2030년)

Healthcare Contract Manufacturing Market Size, Share & Trends Analysis Report By Type (Medical Devices, Pharmaceutical), By End-use (Medical Device Companies), By Region, And Segment Forecasts, 2023 - 2030

US $ 5,950 ￦ 8,302,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,698,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,488,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

헬스케어 수탁제조 시장의 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 헬스케어 수탁제조 시장 규모는 예측 기간 중 CAGR 9.5%로 확대되어 2030년까지 3,475억 달러에 달할 것으로 예상되고 있습니다.

규제 환경의 변화와 신흥 국가로의 오프쇼어링 증가는 예측 기간 중 헬스케어 수탁제조 시장의 성장을 가속할 것으로 예상됩니다. 예를 들어 2023년 6월 FUJIFILM Diosynth Biotechnologies는 도쿄에 영업 사무소를 개설하여 아시아의 제약 및 생명공학 기업에 첨단 치료제 및 생물학적 제제 개발 및 제조 위탁 서비스를 제공한다고 발표했습니다.

COVID-19와 같은 전염병의 출현으로 많은 기업이 수요 증가에 대응하기 위해 생산을 가속화하려고 노력하고 있습니다. 따라서 이러한 기업은 헬스케어 CMO를 고용하여 생산 공정을 가속화하고 전체 비용을 절감하여 의료 제품 수요 증가에 대응하기 위해 의료 제품 생산 속도를 높이고 있습니다, 많은 대형 CMO뿐만 아니라 소규모 CMO들에게도 가장 큰 기회를 창출하고 있습니다. 따라서 전염병은이 산업에 긍정적인 영향을 미쳤습니다.

고급 제품에 대한 수요 증가도 산업 규모를 확대하는 요인 중 하나입니다. OEM(Original Equipment Manufacturers)은 경제적 이익을 얻기 위해 주로 신흥 국가에서 의료기기 제조 활동을 제3자에게 아웃소싱하고 있습니다. 또한 이들 지역에서는 심장질환과 같은 만성질환 환자가 증가하면서 시장 성장에 긍정적인 영향을 미치고 있습니다. 상환 시스템의 변화는 OEM의 비용 억제 조치 채택을 증가시킬 것으로 예상되는 주요 요인 중 일부입니다. 예를 들어 상환 문제가 자금 조달 목표에 영향을 미치지 않도록 하기 위해 기기 제조업체는 제품 개발 초기 단계에서 규제 및 임상 전략과 병행하여 면밀히 계획된 상환 전략을 수립하고 있습니다.

헬스케어 수탁제조 시장 보고서 하이라이트

• 의약품 분야는 낮은 제조 예산과 고도로 정교한 위탁생산 서비스 제공으로 2022년 65.1%의 점유율을 차지하며 시장을 장악했습니다.
• 의료기기 분야는 비용 절감과 제품 출시 기간 단축에 대한 OEM의 압박이 증가함에 따라 CAGR 9.7%로 가장 빠르게 성장할 것으로 예상되는 분야입니다.
• 심장학은 의료기기 위탁생산 부문에서 지배적인 카테고리로 2022년 매출 비중이 20.6%에 달했습니다.
• 아시아태평양은 2023-2030년 10.6%의 고성장이 예상되는데, 이는 다수의 서비스 프로바이더가 존재하고, 비용이 낮으며, 의료기기에 대한 수요가 증가하고 있기 때문입니다.
• 최종 용도별로는 제약 및 바이오 제약 기업 부문이 2022년 55.6%로 가장 높은 매출 점유율을 차지했습니다. 이 부문이 높은 점유율을 보이는 것은 주로 세계에서 생물학적 제제의 승인율이 높아지면서 대량 생산 위탁생산 서비스에 대한 수요가 증가하고 있기 때문입니다.

목차

제1장 조사 방법과 범위

• 시장 세분화와 범위
  • 부문의 정의
  • 유형
  • 최종 용도
• 지역의 범위
• 추정·예측 타임라인
• 목적
  • 목표-1
  • 목표-2
  • 목표-3
• 조사 방법
• 정보 조달
  • 구입한 데이터베이스
  • GVR의 내부 데이터베이스
  • 2차 정보
  • 1차 조사
• 정보 또는 데이터 분석
  • 데이터 분석 모델
• 시장 형성과 검증
• 모델 상세
  • 상품 플로우 분석
  • 모시장 분석
• 2차 정보 리스트
• 약어 리스트

제2장 주요 요약

• 시장 전망
• 부문 전망
• 경쟁 인사이트

제3장 헬스케어 수탁제조 시장 변수, 동향, 범위

• 시장 계통 전망
  • 모시장 전망
  • 관련/보조적인 시장 전망
• 시장 역학
  • 시장 촉진요인 분석
  • 시장 억제요인 분석
  • 업계의 과제
• 헬스케어 수탁제조 시장 분석 툴
  • 업계 분석 : Porter의 산업 분석
  • PESTEL 분석
  • COVID-19의 영향 분석

제4장 헬스케어 수탁제조 시장 : 유형별 부문 분석

• 헬스케어 수탁제조 : 시장 점유율 분석, 2022년 및 2030년
• 의료기기
  • 의료기기 시장, 2018-2030년(100만 달러)
  • 서비스
  • 치료 영역
• 의약품
  • 의약품 시장, 2018-2030(100만 달러)
  • 서비스

제5장 헬스케어 수탁제조 시장 : 최종 용도별 부문 분석

• 헬스케어 수탁제조 : 시장 점유율 분석, 2022년 및 2030년
• 의료기기 기업
  • 의료기기 기업 시장, 2018-2030년(100만 달러)
• 제약회사 및 바이오의약품 회사
  • 제약 및 바이오의약품 기업 시장, 2018-2030(100만 달러)
• 기타
  • 기타 시장, 2018-2030(100만 달러)

제6장 헬스케어 수탁제조 시장 : 지역별 분석

• 지역 시장 점유율 분석, 2022년 및 2030년
• 지역 시장 대시보드
• 세계의 지역 시장 스냅숏
• 북미
  • 시장 추산·예측, 2018-2030년(매출, 100만 달러)
  • 미국
  • 캐나다
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
  • 벨기에
  • 네덜란드
• 아시아태평양
  • 일본
  • 인도
  • 중국
  • 한국
  • 호주
  • 태국
  • 필리핀
  • 말레이시아
  • 뉴질랜드
  • 싱가포르
• 라틴아메리카
  • 브라질
  • 멕시코
  • 아르헨티나
  • 콜롬비아
  • 칠레
• MEA
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트
  • 이스라엘

제7장 경쟁 구도

• 시장 참여 기업의 분류
  • 이노베이터
  • 시장 리더
  • 신규 기업
  • 기업의 시장 점유율 분석, 2022년
• 기업 개요
  • Nordson Corporation.
  • Integer Holdings Corporation
  • Jabil Inc.
  • Viant Technology LLC
  • FLEX LTD.
  • Celestica Inc.
  • Sanmina Corporation
  • Plexus Corp.
  • Phillips-Medisize
  • West Pharmaceutical Services, Inc.
  • Synecco Ltd.
  • Catalent, Inc.
  • Thermo Fisher Scientific Inc.
  • Recipharm AB.
  • Boehringer Ingelheim International GmbH
  • Lonza
  • Samsung Biologics
  • WuXi AppTec
  • FUJIFILM Diosynth Biotechnologies
  • Cambrex Corporation

제8장 KoL 해설/권장사항

KSA

영문 목차

영문목차

Healthcare Contract Manufacturing Market Growth & Trends

The global healthcare contract manufacturing market size is expected to reach USD 347.5 billion by 2030, expanding at a CAGR of 9.5% during the forecast period, according to a new report by Grand View Research, Inc. The changing regulatory landscape coupled with rising offshoring to emerging countries is anticipated to propel the healthcare contract manufacturing market growth over the forecast period. For instance, in June 2023, FUJIFILM Diosynth Biotechnologies announced to have a commercial office in Tokyo, offering contract development and manufacturing services for advanced therapies and biologics to Asian pharmaceutical and biotechnology companies.

Due to the emergence of infections, such as COVD-19 many organizations are attempting to accelerate production to meet the growing demand. Thus, these companies are appointing healthcare CMOs to speed up their production processes, as well as reduce their overall costs to meet the increasing demand for medical products. The worldwide effort to develop a vaccine and therapeutic agent against COVID-19 has created the greatest opportunity for many large as well as small CMOs as the pharmaceutical companies are manufacturing vaccine doses on large scale. Hence, the pandemic had a positive impact on this industry.

Increasing demand for advanced products is another factor driving the industry scale. Original Equipment Manufacturers (OEMs) are outsourcing the manufacturing activities of medical devices to third parties, mainly in developing countries to gain economic benefits. Furthermore, these regions are witnessing rising cases of chronic conditions such as heart disorders, thereby positively affecting the market growth. Changes in reimbursement schemes are some of the major factors anticipated to increase the adoption of cost containment measures by OEMs. For instance, to prevent reimbursement issues from impacting financing goals, device manufacturers are developing a well-planned reimbursement strategy in parallel with their regulatory and clinical strategies in the early phases of product development.

Healthcare Contract Manufacturing Market Report Highlights

• The pharmaceutical segment dominated the market with a share of 65.1% in 2022 owing to a low manufacturing budget and highly sophisticated contract manufacturing service offerings
• The medical devices segment is expected to be the fastest-growing segment with a CAGR of 9.7% owing to increasing pressure on OEMs to reduce costs and enhance the timeline for taking a product to market
• Cardiology is the dominant category in the medical device contract manufacturing segment, with a revenue share of 20.6% in 2022, owing to the rising demand for cardiovascular devices as a result of the increasing prevalence of associated heart conditions
• Asia Pacific is expected to witness lucrative growth of 10.6% from 2023 to 2030, owing to the presence of a large number of service providers, lower costs, and growing demand for medical devices in the region
• Based on end use segment, the pharmaceutical and biopharmaceutical companies category held the highest revenue share of 55.6% in 2022. High segment shares are mainly due to the increasing rate of biologics approval across the globe, thereby boosting demand for its bulk production contract manufacturing services

Table of Content

Chapter 1. Research Methodology And Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Segment Definitions
  • 1.1.2. Type
  • 1.1.3. End Use
• 1.2. Regional Scope
• 1.3. Estimates And Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective-1
  • 1.4.2. Objective-2
  • 1.4.3. Objective-3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information Or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
  • 1.9.2. Parent Market Analysis
• 1.10. List Of Secondary Sources
• 1.11. List Of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Healthcare Contract Manufacturing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Implementation of international standards by contract manufacturers
    • 3.2.1.2. Drug shortage driving the demand for pharmaceutical development
    • 3.2.1.3. Commercial success of biologics for clinical use
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Regulatory and legal compliance
    • 3.2.2.2. Threat of information loss
  • 3.2.3. Industry Challenges
    • 3.2.3.1. Managing relationships
• 3.3. Healthcare Contract Manufacturing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat Of New Entrant
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Healthcare Contract Manufacturing Market: Type Segment Analysis

• 4.1 Healthcare Contract Manufacturing: Market Share Analysis, 2022 & 2030
• 4.2 Medical Device
  • 4.2.1 Medical device market, 2018 - 2030 (USD Million)
  • 4.2.2 Service
    • 4.2.2.1 Accessories manufacturing
    • 4.2.2.1.1 Accessories manufacturing market, 2018 - 2030 (USD Million)
    • 4.2.2.2 Assembly manufacturing
    • 4.2.2.2.1 Assembly manufacturing market, 2018 - 2030 (USD Million)
    • 4.2.2.3 Component manufacturing
    • 4.2.2.3.1 Component manufacturing market, 2018 - 2030 (USD Million)
    • 4.2.2.4 Device manufacturing
    • 4.2.2.4.1 Device manufacturing market, 2018 - 2030 (USD Million)
  • 4.2.3 Therapeutic area
    • 4.2.3.1 Cardiology
    • 4.2.3.1.1 Cardiology market, 2018 - 2030 (USD Million)
    • 4.2.3.2 Diagnostic imaging
    • 4.2.3.2.1 Diagnostic imaging market, 2018 - 2030 (USD Million)
    • 4.2.3.3 Orthopedic
    • 4.2.3.3.1 Orthopedic market, 2018 - 2030 (USD Million)
    • 4.2.3.4 IVD
    • 4.2.3.4.1 IVD market, 2018 - 2030 (USD Million)
    • 4.2.3.5 Ophthalmic
    • 4.2.3.5.1 Ophthalmic market, 2018 - 2030 (USD Million)
    • 4.2.3.6 General & plastic surgery
    • 4.2.3.6.1 General & plastic surgery market, 2018 - 2030 (USD Million)
    • 4.2.3.7 Drug delivery
    • 4.2.3.7.1 Drug delivery market, 2018 - 2030 (USD Million)
    • 4.2.3.8 Dental
    • 4.2.3.8.1 Dental market, 2018 - 2030 (USD Million)
    • 4.2.3.9 Endoscopy
    • 4.2.3.9.1 Endoscopy market, 2018 - 2030 (USD Million)
    • 4.2.3.10 Diabetes care
    • 4.2.3.10.1 Diabetes care market, 2018 - 2030 (USD Million)
    • 4.2.3.11 Others
    • 4.2.3.11.1 Others market, 2018 - 2030 (USD Million)
• 4.3 Pharmaceutical
  • 4.3.1 Pharmaceutical market, 2018 - 2030 (USD Million)
  • 4.3.2 Service
    • 4.3.2.1 API/bulk drugs
    • 4.3.2.1.1 API/bulk drugs market, 2018 - 2030 (USD Million)
    • 4.3.2.2 Advanced drug delivery formulations
    • 4.3.2.2.1 Advanced drug delivery formulations market, 2018 - 2030 (USD Million)
    • 4.3.2.3 Packaging
    • 4.3.2.3.1 Packaging market, 2018 - 2030 (USD Million)
    • 4.3.2.4 Finished dose formulations
    • 4.3.2.4.1 Finished dose formulations market, 2018 - 2030 (USD Million)
    • 4.3.2.4.2 Solid
    • 4.3.2.4.2.1 Solid market, 2018 - 2030 (USD Million)
    • 4.3.2.4.3 Liquid
    • 4.3.2.4.3.1 Liquid market, 2018 - 2030 (USD Million)
    • 4.3.2.4.4 Semisolid formulations
    • 4.3.2.4.4.1 Semisolid formulations market, 2018 - 2030 (USD Million)

Chapter 5. Healthcare Contract Manufacturing Market: End Use Segment Analysis

• 5.1 Healthcare Contract Manufacturing: Market Share Analysis, 2022 & 2030
• 5.2 Medical Device Companies
  • 5.2.1 Medical device companies market, 2018 - 2030 (USD Million)
• 5.3 Pharmaceutical & Biopharmaceutical Companies
  • 5.3.1 Pharmaceutical & Biopharmaceutical Companies market, 2018 - 2030 (USD Million)
• 5.4 Others
  • 5.4.1 Others market, 2018 - 2030 (USD Million)

Chapter 6. Healthcare Contract Manufacturing Market: Regional Analysis

• 6.1. Regional Market Share Analysis, 2022 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Global Regional Market Snapshot
• 6.4. North America
  • 6.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Competitive Scenario
    • 6.4.2.3. Regulatory Framework
    • 6.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
  • 6.4.3. Canada
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Competitive Scenario
    • 6.4.3.3. Regulatory Framework
    • 6.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
• 6.5. Europe
  • 6.5.1. UK
    • 6.5.1.1. Key Country Dynamics
    • 6.5.1.2. Competitive Scenario
    • 6.5.1.3. Regulatory Framework
    • 6.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
  • 6.5.2. Germany
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Competitive Scenario
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
  • 6.5.3. France
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Competitive Scenario
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
  • 6.5.4. Italy
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Competitive Scenario
    • 6.5.4.3. Regulatory Framework
    • 6.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
  • 6.5.5. Spain
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Competitive Scenario
    • 6.5.5.3. Regulatory Framework
    • 6.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
  • 6.5.6. Denmark
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Competitive Scenario
    • 6.5.6.3. Regulatory Framework
    • 6.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
  • 6.5.7. Sweden
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Competitive Scenario
    • 6.5.7.3. Regulatory Framework
    • 6.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
  • 6.5.8. Norway
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Competitive Scenario
    • 6.5.8.3. Regulatory Framework
    • 6.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
  • 6.5.9. Belgium
    • 6.5.9.1. Key Country Dynamics
    • 6.5.9.2. Competitive Scenario
    • 6.5.9.3. Regulatory Framework
    • 6.5.9.4. Belgium Market Estimates and Forecasts, 2018 - 2030
  • 6.5.10. Netherlands
    • 6.5.10.1. Key Country Dynamics
    • 6.5.10.2. Competitive Scenario
    • 6.5.10.3. Regulatory Framework
    • 6.5.10.4. Netherlands Market Estimates and Forecasts, 2018 - 2030
• 6.6. Asia Pacific
  • 6.6.1. Japan
    • 6.6.1.1. Key Country Dynamics
    • 6.6.1.2. Competitive Scenario
    • 6.6.1.3. Regulatory Framework
    • 6.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
  • 6.6.2. India
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Competitive Scenario
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. India Market Estimates and Forecasts, 2018 - 2030
  • 6.6.3. China
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Competitive Scenario
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. China Market Estimates and Forecasts, 2018 - 2030
  • 6.6.4. South Korea
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Competitive Scenario
    • 6.6.4.3. Regulatory Framework
    • 6.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
  • 6.6.5. Australia
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Competitive Scenario
    • 6.6.5.3. Regulatory Framework
    • 6.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
  • 6.6.6. Thailand
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Competitive Scenario
    • 6.6.6.3. Regulatory Framework
    • 6.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
  • 6.6.7. Philippines
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Competitive Scenario
    • 6.6.7.3. Regulatory Framework
    • 6.6.7.4. Philippines Market Estimates and Forecasts, 2018 - 2030
  • 6.6.8. Malaysia
    • 6.6.8.1. Key Country Dynamics
    • 6.6.8.2. Competitive Scenario
    • 6.6.8.3. Regulatory Framework
    • 6.6.8.4. Malaysia Market Estimates and Forecasts, 2018 - 2030
  • 6.6.9. New Zealand
    • 6.6.9.1. Key Country Dynamics
    • 6.6.9.2. Competitive Scenario
    • 6.6.9.3. Regulatory Framework
    • 6.6.9.4. New Zealand Market Estimates and Forecasts, 2018 - 2030
  • 6.6.10. Singapore
    • 6.6.10.1. Key Country Dynamics
    • 6.6.10.2. Competitive Scenario
    • 6.6.10.3. Regulatory Framework
    • 6.6.10.4. Singapore Market Estimates and Forecasts, 2018 - 2030
• 6.7. Latin America
  • 6.7.1. Brazil
    • 6.7.1.1. Key Country Dynamics
    • 6.7.1.2. Competitive Scenario
    • 6.7.1.3. Regulatory Framework
    • 6.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
  • 6.7.2. Mexico
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Competitive Scenario
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Competitive Scenario
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030
  • 6.7.4. Colombia
    • 6.7.4.1. Key Country Dynamics
    • 6.7.4.2. Competitive Scenario
    • 6.7.4.3. Regulatory Framework
    • 6.7.4.4. Colombia Market Estimates and Forecasts, 2018 - 2030
  • 6.7.5. Chile
    • 6.7.5.1. Key Country Dynamics
    • 6.7.5.2. Competitive Scenario
    • 6.7.5.3. Regulatory Framework
    • 6.7.5.4. Chile Market Estimates and Forecasts, 2018 - 2030
• 6.8. MEA
  • 6.8.1. South Africa
    • 6.8.1.1. Key Country Dynamics
    • 6.8.1.2. Competitive Scenario
    • 6.8.1.3. Regulatory Framework
    • 6.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
  • 6.8.2. Saudi Arabia
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Competitive Scenario
    • 6.8.2.3. Regulatory Framework
    • 6.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
  • 6.8.3. UAE
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Competitive Scenario
    • 6.8.3.3. Regulatory Framework
    • 6.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
  • 6.8.4. Kuwait
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Competitive Scenario
    • 6.8.4.3. Regulatory Framework
    • 6.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030
  • 6.8.5. Israel
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Competitive Scenario
    • 6.8.5.3. Regulatory Framework
    • 6.8.5.4. Israel Market Estimates and Forecasts, 2018 - 2030

Chapter 7. Competitive Landscape

• 7.1. Market Participant Categorization
  • 7.1.1. Innovators
  • 7.1.2. Market Leaders
  • 7.1.3. Emerging Players
  • 7.1.4. Company Market Share Analysis, 2022
• 7.2. Company Profiles
  • 7.2.1 Nordson Corporation.
    • 7.2.1.1 Company overview
    • 7.2.1.2 Financial performance
    • 7.2.1.3 Service benchmarking
    • 7.2.1.4 Strategic initiatives
  • 7.2.2 Integer Holdings Corporation
    • 7.2.2.1 Company overview
    • 7.2.2.2 Financial performance
    • 7.2.2.3 Service benchmarking
    • 7.2.2.4 Strategic initiatives
  • 7.2.3 Jabil Inc.
    • 7.2.3.1 Company overview
    • 7.2.3.2 Financial performance
    • 7.2.3.3 Service benchmarking
    • 7.2.3.4 Strategic initiatives
  • 7.2.4 Viant Technology LLC
    • 7.2.4.1 Company overview
    • 7.2.4.2 Service benchmarking
    • 7.2.4.3 Strategic initiatives
  • 7.2.5 FLEX LTD.
    • 7.2.5.1 Company overview
    • 7.2.5.2 Financial performance
    • 7.2.5.3 Service benchmarking
    • 7.2.5.4 Strategic initiatives
  • 7.2.6 Celestica Inc.
    • 7.2.6.1 Company overview
    • 7.2.6.2 Financial performance
    • 7.2.6.3 Service benchmarking
    • 7.2.6.4 Strategic initiatives
  • 7.2.7 Sanmina Corporation
    • 7.2.7.1 Company overview
    • 7.2.7.2 Financial performance
    • 7.2.7.3 Service benchmarking
    • 7.2.7.4 Strategic initiatives
  • 7.2.8 Plexus Corp.
    • 7.2.8.1 Company overview
    • 7.2.8.2 Financial performance
    • 7.2.8.3 Service benchmarking
    • 7.2.8.4 Strategic initiatives
  • 7.2.9 Phillips-Medisize
    • 7.2.9.1 Company overview
    • 7.2.9.2 Service benchmarking
    • 7.2.9.3 Strategic initiatives
  • 7.2.10 West Pharmaceutical Services, Inc.
    • 7.2.10.1 Company overview
    • 7.2.10.2 Financial performance
    • 7.2.10.3 Service benchmarking
    • 7.2.10.4 Strategic initiatives
  • 7.2.11 Synecco Ltd.
    • 7.2.11.1 Company overview
    • 7.2.11.2 Service benchmarking
  • 7.2.12 Catalent, Inc.
    • 7.2.12.1 Company overview
    • 7.2.12.2 Financial performance
    • 7.2.12.3 Service benchmarking
    • 7.2.12.4 Strategic initiatives
  • 7.2.13 Thermo Fisher Scientific Inc.
    • 7.2.13.1 Company overview
    • 7.2.13.2 Financial performance
    • 7.2.13.3 Service benchmarking
    • 7.2.13.4 Strategic initiatives
  • 7.2.14 Recipharm AB.
    • 7.2.14.1 Company overview
    • 7.2.14.2 Financial performance
    • 7.2.14.3 Service benchmarking
    • 7.2.14.4 Strategic initiatives
  • 7.2.15 Boehringer Ingelheim International GmbH
    • 7.2.15.1 Company overview
    • 7.2.15.2 Financial performance
    • 7.2.15.3 Service benchmarking
    • 7.2.15.4 Strategic initiatives
  • 7.2.16 Lonza
    • 7.2.16.1 Company overview
    • 7.2.16.2 Financial performance
    • 7.2.16.3 Service benchmarking
    • 7.2.16.4 Strategic initiatives
  • 7.2.17 Samsung Biologics
    • 7.2.17.1 Company overview
    • 7.2.17.2 Financial performance
    • 7.2.17.3 Service benchmarking
    • 7.2.17.4 Strategic initiatives
  • 7.2.18 WuXi AppTec
    • 7.2.18.1 Company overview
    • 7.2.18.2 Financial performance
    • 7.2.18.3 Service benchmarking
    • 7.2.18.4 Strategic initiatives
  • 7.2.19 FUJIFILM Diosynth Biotechnologies
    • 7.2.19.1 Company overview
    • 7.2.19.2 Financial performance
    • 7.2.19.3 Service benchmarking
    • 7.2.19.4 Strategic initiatives
  • 7.2.20 Cambrex Corporation
    • 7.2.20.1 Company overview
    • 7.2.20.2 Financial performance
    • 7.2.20.3 Service benchmarking
    • 7.2.20.4 Strategic initiatives

Chapter 8. KoL Commentary/Recommendations

관련자료